Compare CRTO & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRTO | GPCR |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Advertising | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2013 | 2023 |
| Metric | CRTO | GPCR |
|---|---|---|
| Price | $20.40 | $69.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $38.67 | ★ $69.57 |
| AVG Volume (30 Days) | 471.4K | ★ 2.2M |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.79 | N/A |
| EPS | ★ 3.00 | N/A |
| Revenue | ★ $1,956,800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.42 | N/A |
| P/E Ratio | $7.01 | ★ N/A |
| Revenue Growth | ★ 0.53 | N/A |
| 52 Week Low | $19.00 | $13.22 |
| 52 Week High | $47.27 | $94.90 |
| Indicator | CRTO | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 49.13 | 85.42 |
| Support Level | $19.00 | $30.94 |
| Resistance Level | $21.48 | $36.09 |
| Average True Range (ATR) | 0.78 | 5.95 |
| MACD | 0.08 | 1.87 |
| Stochastic Oscillator | 56.45 | 61.04 |
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.